TuHURA Biosciences, Inc./NV

From time to time, we may be involved in various disputes and litigation matters that arise in the ordinary course of business. As of the date of this Annual Report, we are not party to any material legal matters or claims other than the following:

On December 12, 2025, we filed an action filed in the Delaware Court of Chancery styled TuHURA Biosciences, Inc. v. VGXI, Inc. and GeneOne Life Sciences, Inc., C.A. No. 2025-1447-NAC (the “Action”). This is an action for breach of contract concerning the defendants’ alleged failures to produce GMP-grade plasmid DNA on a timeline that would enable us to fulfill our obligations to the FDA for our clinical trial for its Merkel cell carcinoma treatment and the defendants’ alleged fraud in inducing us to enter the contract and subsequently refrain from exercising our rights to terminate the contract and seek cover. The case is in its early stages and discovery has not yet commenced. The complaint was filed on December 12, 2025, and we are waiting for defendants’ response to the complaint. We intend to vigorously pursue our claims against the defendants while remaining open to engaging in reasonable and productive settlement discussions.